Renibus Therapeutics Strengthens IP Position with Additional US Patent

Michael Jaramillo2022-10-15T15:57:00-07:00April 13, 2022|

Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding

Michael Jaramillo2022-10-15T15:57:06-07:00February 15, 2022|

Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021

Michael Jaramillo2022-10-15T15:57:11-07:00October 28, 2021|

Rénibus Therapeutics® Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury

Michael Jaramillo2022-10-15T15:57:16-07:00March 11, 2021|

Rénibus Therapeutics® to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference

Michael Jaramillo2022-10-15T15:57:24-07:00February 25, 2021|

Rénibus Therapeutics® Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant

Michael Jaramillo2022-10-15T15:57:30-07:00February 16, 2021|

Presentations at the American Society of Nephrology Kidney Week 2020

Michael Jaramillo2022-10-15T15:57:36-07:00October 19, 2020|

Renibus Therapeutics® Announces Abstract Presentation at the 2020 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Annual Congress

Dallas, June 09, 2020 (GLOBE NEWSWIRE) — Renibus [...]

Michael Jaramillo2022-10-15T16:11:58-07:00June 9, 2020|

A Pharmacologic “Stress Test” for Assessing Select Antioxidant Defenses in Patients with CKD

Michael Jaramillo2022-10-15T16:00:07-07:00May 15, 2020|

Parenteral Iron Sucrose-Induced Renal Preconditioning: Differential Ferritin Heavy and Light Chain Expression in Plasma, Urine and Internal Organs.

Michael Jaramillo2022-10-15T16:01:09-07:00December 1, 2019|